B+
Bull case
25%
Probability
Target price
$62.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
ALKS
AlkermesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$53.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.5
Score
AI commentary
Primary-source tone is constructive on commercial execution and the orexin pipeline, but the earnings-quality mix is cautious rather than clearly bullish. The packet lacks usable analyst-revision, options, short-interest, employee-sentiment, and social-coverage data; those missing channels are not positive evidence. Overall evidence supports monitoring rather than an aggressive directional thesis.
RankAlpha Sentiment Codex - 2026-08-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-28catalystQ2 commercial growth with mixed earnings qualityMedium impact
Q2 revenue increased to $496.0 million from $390.7 million and adjusted EBITDA rose to $139.2 million from $126.5 million, but GAAP net income fell to $0.5 million from $87.1 million. This supports commercial momentum but limits near-term rerating confidence [#SEC-8K-2026-07-28].
2026-08-01eventPlanned CEO transitionMedium impact
Blair Jackson assumed the CEO role on August 1, 2026, while Richard Pops continues as chairman. The transition appears planned, but execution under the new leadership structure remains a monitoring point [#SEC-8K-2026-07-28].
2026-12-31catalystALKS 7290 ADHD dataHigh impact
Management expects the first ADHD data for ALKS 7290 in the coming months. Positive data could strengthen the orexin 2 receptor portfolio thesis, while a weak or delayed readout would pressure expectations [#SEC-8K-2026-07-28].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology